Prof Javier Puente (Complutense University Hospital Clinico, Madrid, Spain), Prof Viktor Grünwald (University Hospital Essen, Essen, Germany), Prof James Larkin (The Royal Marsden Hospital, London, UK) and Prof Jens Bedke (Tübingen University Hospital, Tübingen, Germany) discuss the latest developments in the treatment of mRCC from ASCO GU 2021.
Initially, they discuss the studies presented at ASCO GU 2021 regarding the 1st line treatments, other options and management of patients with metastatic renal cell carcinoma. They discuss the data from the CLEAR and CheckMate 9ER studies.
They further talk about patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214 and outcomes for patients in the pembrolizumab axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study. They then move on to discuss second and third line treatment and the recent studies regarding that. In the end they discuss what the future looks like for these patients in terms of new treatment options.